DBV Technologies (NASDAQ:DBVT) Shares Down 8.2% – Here’s Why

DBV Technologies S.A. (NASDAQ:DBVT)’s share price was down 8.2% during mid-day trading on Tuesday . The stock traded as low as $16.29 and last traded at $16.6360. Approximately 66,810 shares changed hands during trading, a decline of 77% from the average daily volume of 292,488 shares. The stock had previously closed at $18.12.

Wall Street Analyst Weigh In

Several research analysts have issued reports on DBVT shares. Citizens Jmp raised their price objective on shares of DBV Technologies from $47.00 to $55.00 and gave the stock a “market outperform” rating in a research report on Friday, May 1st. Guggenheim reissued a “buy” rating and set a $51.00 price objective on shares of DBV Technologies in a research report on Monday, May 4th. Citigroup reissued an “outperform” rating on shares of DBV Technologies in a research report on Friday, May 1st. Finally, Wall Street Zen raised shares of DBV Technologies from a “sell” rating to a “hold” rating in a research report on Saturday, May 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, DBV Technologies has a consensus rating of “Moderate Buy” and a consensus target price of $48.50.

DBV Technologies Trading Down 5.8%

The company has a market cap of $1.01 billion, a price-to-earnings ratio of -3.83 and a beta of -0.99. The company’s 50 day moving average price is $19.36 and its 200 day moving average price is $19.72.

DBV Technologies (NASDAQ:DBVT) last released its earnings results on Thursday, April 30th. The company reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.42). DBV Technologies had a negative net margin of 2,895.37% and a negative return on equity of 129.88%. The business had revenue of $0.90 million during the quarter, compared to analyst estimates of $1.11 million. Sell-side analysts predict that DBV Technologies S.A. will post -0.47 earnings per share for the current year.

Institutional Trading of DBV Technologies

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Allworth Financial LP acquired a new stake in shares of DBV Technologies in the fourth quarter valued at about $32,000. Royal Bank of Canada acquired a new stake in shares of DBV Technologies in the fourth quarter valued at about $34,000. GAMMA Investing LLC lifted its stake in shares of DBV Technologies by 38.4% in the fourth quarter. GAMMA Investing LLC now owns 2,680 shares of the company’s stock valued at $51,000 after purchasing an additional 744 shares during the period. Truvestments Capital LLC lifted its stake in shares of DBV Technologies by 71.3% in the fourth quarter. Truvestments Capital LLC now owns 3,892 shares of the company’s stock valued at $75,000 after purchasing an additional 1,620 shares during the period. Finally, Persistent Asset Partners Ltd acquired a new stake in shares of DBV Technologies in the fourth quarter valued at about $115,000. Institutional investors and hedge funds own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.